PEGylated PLGA nanoparticles for the improved delivery of doxorubicin

Abstract We hypothesize that the efficacy of doxorubicin (DOX) can be maximized and dose-limiting cardiotoxicity minimized by controlled release from PEGylated nanoparticles. To test this hypothesis, a unique surface modification technique was used to create PEGylated poly(lactic-co-glycolic acid) (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nanomedicine 2009-12, Vol.5 (4), p.410-418
Hauptverfasser:	Park, Jason, MS, Fong, Peter M., PhD, Lu, Jing, PhD, Russell, Kerry S., MD, PhD, Booth, Carmen J., DVM, PhD, Saltzman, W. Mark, PhD, Fahmy, Tarek M., PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adsorption - drug effects Animals Cattle Cell Death - drug effects Doxorubicin Doxorubicin - administration & dosage Doxorubicin - blood Doxorubicin - pharmacokinetics Doxorubicin - therapeutic use Drug delivery Drug Delivery Systems - methods Drug Delivery Systems - standards Female Glycolates - chemistry Glycolates - pharmacokinetics Heart - drug effects Heart - physiopathology Internal Medicine Lactic Acid Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - physiopathology Mice Mice, Inbred BALB C Nanoparticle Nanoparticles - administration & dosage Nanoparticles - toxicity Nanoparticles - ultrastructure Particle Size PEGylated PLGA Polyethylene Glycols - chemistry Polyethylene Glycols - pharmacokinetics Polyglycolic Acid Polylactic Acid-Polyglycolic Acid Copolymer Serum Albumin, Bovine - metabolism Surface Properties - drug effects Tissue Distribution - drug effects Ventricular Function, Left - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!